• FFP-01 Non-Formulary Drug Use Request Procedure and/or Request for Addition to/Deletion from Formulary
  • Non-Formulary Request Form
  • Request for Addition to LTC Formulary
• FPP-03 Transitional Medication Supply from Acute Care to Long Term Care
• FPP-04 Formulary Rationale and Principles
• FPP-06 Criteria for Listing Drug Products on the LTC Formulary
• FPP-07 Special Access Drug Use Request Procedure
• FPP-08 Challenge Protocol
• FPP-09 Automatic Stop Orders
• FPP-10 Compound Coverage Criteria
• FPP-11 Opioid Safety Review
• FPP-12 Use of Hold Orders in LTC
• FPP-13 Biosimilar Initiative Implementation in Calgary Zone LTC

Acute Discharge Documents

• The Calgary Acute Care sites are transitioning to the Continuing Care Discharge Communication Project in phases. Please contact the client’s discharging hospital unit for current practice.

Position Statements

• Polyethylene Glycol 3350 Laxative and Thickening Agents

Wardstock/Statbox Lists

• LTC Wardstock and Statbox Lists

• Full formulary listing of all medications covered by the Calgary LTC Formulary

• Automatic Substitution List-01
• ASL-02: ACE Inhibitors
• ASL-03: glaucoma, topical medical treatment
• ASL-05: proton pump inhibitors

• High Cost Drug List - Drug Use Conditions
• Aripiprazole and Brexpiprazole (SA-25)
• Botulinum Toxin Type A (HCD-16)
  • Form - Initial
  • Form - Renewal
• Cholinesterase Inhibitors and memantine (HCD-09)
  • form
• Clozapine (HCD-07)
• Darbepoetin and Epoetin Alpha (HCD-04)
  • Form
• Fentanyl Patch (HCD-08)
  • Form
• Fosfomycin (HCD-24)
  • form
• Heparins, Low Molecular Weight (HCD-06)
  • form
  • HCD-06 Supplement: LMWH for VTE Prophylaxis in LTC residents with COVID-19 infection
• Imiquimod (HCD-02)
  • Form
• Influenza Antiviral Agents: Oseltamivir
  • Oseltamivir (SA-03)
• Long Acting Injectable Atypical Antipsychotics
• Naltrexone (HCD-27)
• Ondansetron - 5HT-3 Receptor Antagonist (SA-31)
• Pregabalin (SA-28)
• SGLT-2 Inhibitors & DPP-4 Inhibitors (SA-30)
• Terbinafine oral (HCD-26)
• Vancomycin (HCD-22)
  • Form

• Restricted Use Drug List - Drug Use Conditions
• Restricted Use Miscellaneous Drugs (RS-11)
• angiotensin receptor blockers (RS-34)
• antiarrythmics (RS-28)
• anticholinergics, topical (RS-38)
• asthma/COPD management (RS-29)
  • Inhaled Medication Assessment Tool
• bisphosphonates (RS-19)
• budesonide, oral (RS-45)
• buspirone (RS-03)
• calcitonin injection (RS-33)
• cox 2 inhibitors (RS-25)
• cyproterone (RS-42)
• fentanyl citrate injection (RS-31)
• finaseride and dutasteride (RS-13)
• fluconazole (RS-23)
• fluoroquinolones (RS-02)
• fluoxetine (RS-09)
• gatifloxacin and moxifloxacin hydrochloride (RS-10)
• insulins, rapid acting (RS-40)
• levodopa/carbidopa, benserazide HCL, selegiline (RS-35)
• methotrexate (RS-41)
• metronidazole (RS-47)
• mirabegron (RS-46)
• nebulized medication (RS-21)
• nitrofurantoin (RS-32)
• nicotine replacement (RS-26)
• phytonadione (vitamin K1) (RS-05)
• probiotics (RS-20)
• proton pump inhibitors (RS-04)
• statins (RS-16)
• terbinafine cream (RS-17)
• tizanidine (RS-36) 

• Anti-Retroviral/Immunosupprants (for organ and bone marrow transplant)/Pulmonary Hypertension/Cystic Fibrosis/Anti-Neoplastics/Anti-Tuberculotic